DSIP (Delta Sleep-Inducing Peptide): What It Is, How It Works, and What the Research Shows

At a glance: DSIP is a nine-amino-acid peptide discovered in 1977 that increased deep (delta) sleep in rabbits. Small human studies in the 1980s and 1990s gave mixed results, its receptor and gene have never been found, and it is not FDA-approved. In July 2026 an FDA advisory committee voted against allowing it in compounding, the only one of seven peptides reviewed to be rejected.

What is DSIP?

DSIP stands for delta sleep-inducing peptide. It is a nonapeptide (nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu). In compounding and regulatory documents it is called emideltide.

It was discovered in 1977 by Swiss researchers Schoenenberger and Monnier, who took blood from rabbits put into a sleep-like state by electrically stimulating part of the brain. A substance in that blood increased slow-wave (delta) brain activity when given to other rabbits. They identified the peptide, made it synthetically, and found that only the complete nine-amino-acid sequence worked.

How does DSIP work?

Nearly 50 years after its discovery, nobody knows for sure. A 2006 review in the Journal of Neurochemistry titled it "a still unresolved riddle" and listed the open problems:

• No receptor has been identified that DSIP binds to
• No gene coding for it has been found in humans or animals; some researchers have suggested it may come from gut bacteria
• Inconsistent sleep effects across studies and species
• Broad, nonspecific activity: it has been linked to stress hormones, circadian rhythm, pain signaling and hormone release, without a clear pathway for any of them

What the research shows so far

All human studies were small and short, and many are decades old. No large, modern, placebo-controlled trial exists.

Why it gets attention

• Sleep problems are common, and a natural-sounding "sleep peptide" has wide appeal
• Its name promises deep sleep, which the evidence only partly supports
• Wellness clinics and online sellers market it for sleep, stress and recovery
• The 2026 FDA review, which considered it for chronic insomnia, narcolepsy and opioid withdrawal

How it is given

In human studies DSIP was given by injection into a vein; products sold today are mainly for injection under the skin, usually marketed for evening use. There is no FDA-approved product and no established human dose, and this page does not provide dosing guidance.

What about side effects?

In the small studies, DSIP was generally reported as well tolerated, with few side effects noted. But those studies were short and involved few people, so rare or long-term effects would not have shown up. Reported or theorized concerns include headache, grogginess, and effects on stress and hormone systems that remain poorly understood.

• Unknown long-term safety: no study has followed people using it for months or years.
• Product quality: online products may not contain what the label says, and injectables may not be sterile.
• Sleep conditions need diagnosis: persistent insomnia can signal sleep apnea, depression or other treatable problems.

Regulatory status

• Not FDA-approved for any use.
• In April 2026 FDA removed emideltide (DSIP) from its "Category 2" list of substances raising significant safety concerns. That was not a safety finding and did not make it eligible for compounding.
• In July 2026 FDA's Pharmacy Compounding Advisory Committee reviewed it for opioid withdrawal, chronic insomnia and narcolepsy and voted 7 to 6 against adding it to the compounding list. It was the only one of seven peptides reviewed that the panel rejected. FDA's own reviewers had also recommended against it, citing a lack of clinical evidence.
• The vote is advisory and FDA has not issued a final decision, but current rules are unchanged: it cannot be legally compounded, and "research use" products are not approved for human use.

The bottom line

DSIP is a genuinely interesting piece of sleep science history, but after nearly five decades its mechanism is still unknown and the human evidence amounts to a handful of small, mixed studies. Even an FDA advisory panel that approved six other peptides voted against it. Anyone struggling with sleep should see a clinician, since effective, well-studied treatments for insomnia exist.

Frequently asked questions

What is DSIP?

A nine-amino-acid peptide first isolated in 1977 from the blood of rabbits in an induced sleep state.

How is DSIP taken?

Injection in published studies.

Is DSIP FDA approved?

Not approved.

That means no regulator has reviewed its safety, effectiveness or manufacturing quality for this use.

What has research shown about DSIP?

• Sleep patterns in animal studies and small human studies, with mixed results.
• Stress responses in animal studies.

What side effects have been reported?

• Not well characterised; older human studies were small and reported few problems

Serious or less common risks are listed in the Side Effects section above.

What is still unknown about its safety?

Most of it. DSIP has not been through the trials that establish long-term safety in people, and products sold online are made by unregulated labs. Independent testing of online peptides has repeatedly found contents that do not match the label.

References

1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (sleep)-inducing peptide. PNAS. 1977. View source
2. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. 1984. View source
3. PeptideJournal: DSIP sleep research, clinical study analysis (summary of Schneider-Helmert, Bes et al. and Kovalzon reviews). View source
4. STAT News: FDA peptide compounding panel backs epitalon, rejects emideltide (July 24, 2026). View source
5. RAPS: FDA advisory committee backs two more peptides, rejects one for compounding list (2026). View source
6. FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee. View source
7. Rite Aid: DSIP overview. View source